Your session is about to expire
← Back to Search
Antibiotic
Vancomycin for Spinal Disorders
Phase 4
Recruiting
Led By Mohamed Soliman, MD
Research Sponsored by Windsor-Essex Compassionate Care Community
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients requiring surgery due to any spine disease
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
Study Summary
This trial will help researchers determine whether intra-wound vancomycin powder is effective in reducing post-surgical infection rates in spine surgery patients.
Who is the study for?
This trial is for patients needing surgery for any spinal disease. It aims to see if applying vancomycin powder into the surgical wound can prevent infections after spine surgery.Check my eligibility
What is being tested?
The study is testing whether intrawound vancomycin powder reduces post-surgical infections in spine surgeries. Patients are randomly assigned to receive either the vancomycin treatment or no treatment (control group).See study design
What are the potential side effects?
While not explicitly listed, potential side effects may include allergic reactions, irritation at the wound site, and possibly antibiotic resistance.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Rate of Infection
Secondary outcome measures
Complications
Trial Design
2Treatment groups
Active Control
Group I: VancomycinActive Control1 Intervention
For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.
Group II: ControlActive Control1 Intervention
Participants will not be receiving vancomycin.
Find a Location
Who is running the clinical trial?
Windsor-Essex Compassionate Care CommunityLead Sponsor
3 Previous Clinical Trials
2,500 Total Patients Enrolled
Cairo UniversityOTHER
3,310 Previous Clinical Trials
1,541,859 Total Patients Enrolled
Mohamed Soliman, MDPrincipal InvestigatorWestern University
1 Previous Clinical Trials
400 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger